Investors

Recent Releases

April 16, 2026

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation plan GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company has closed on a

April 16, 2026

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via

April 9, 2026

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN ® Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program).